What is the Actual Clinical Benefit of Using Low Dose Prednisone Along with Prostate Cancer Chemotherapy with Docetaxel?

Randomized trials have clearly demonstrated that when low dose Prednisone (P) is combined with docetaxel chemotherapy (D) to treat prostate cancer there is a survival benefit. What is the role of the prednisone and does it actually provide any additional benefit to the docetaxel treatment itself? To answer this question a retrospective study was performed that investigated whether the co-administration of low-dose glucocorticoids (P) has any additional clinical benefits over D alone. The researchers took the records of 358 men with metastatic castration-resistant prostate cancer treated consecutively with either docetaxel (D) 75mg/m(2) every 3 weeks (n = 124) or D [...]

Using Low Dose Prednisone in First-Line Docetaxel Treatment Improves The Quality of Life (QoL) For Men With Prostate Cancer

Clinical trials are used to both demonstrate that a drug or treatment has efficacy (extends life or improves the quality of life). They also are used as the vehicle to obtain approval from the governmental body responsible for monitoring and approving their use. How the trial is set up will directly dictate the eventual approved label (the approved dose as well as any additional drugs or treatments to be administered along side the investigational drug, etc.). This doesn’t necessarily mean that the label is actually the best option for use as other untested doses or co-administered drugs could still be [...]

Is There A Clinical Benefit Derived From Using Low Dose Prednisone With First Line Docetaxel Treatment In Men With Castrate Resistant Prostate Cancer?

There have been some randomized studies that have shown that when prednisone is used in combination with docetaxel (chemotherapy) there is an improved survival in men who have metastatic castration-resistant prostate cancer (mCRPC). To add to our understanding of the possible clinical value of this combination of drugs some researchers have retrospectively evaluated whether the co-administration of low-dose glucocorticoids with docetaxel has clinical benefits. They evaluated the records of 358 men with metastatic castration-resistant prostate cancer (mCRPC) who were treated  with either docetaxel or docetaxel and prednisone. They found that the men treated with docetaxel alone had a higher incidence [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー